OR WAIT null SECS
The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
MilliporeSigma announced on Oct. 19, 2020 that it has selected Combined Therapeutics, a pre-clinical-stage biotechnology company located in Cambridge, MA, as the North American winner of its 2020 Advance Biotech Grant Program.
The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system, a MilliporeSigma press release said. Through the program, Combined Therapeutics will receive MilliporeSigma products and consultation in downstream processing, formulation excipients, and sterile filtration.
“We help pioneering biotech companies bring lifesaving drugs to market faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in the press release. “Combined Therapeutics’ platform shows promise to treat liver cancer, which affects thousands of people across the world each year.”
“MilliporeSigma’s expertise in large biomolecule filtration, scale-up and extensive range of excipients will play a pivotal role in moving this project forward to GMP and clinical trials,” added Romain Micol, CEO, Combined Therapeutics, in the press release. “We are honored to have been selected as the winner of MilliporeSigma’s Advance Biotech Grant, and we look forward to the collaboration.”